Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events
On November 1, 2024, certain shareholders (the “Selling Shareholders”) of Harmony Biosciences Holdings, Inc. (the “Company”) sold 8,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (“Common Stock”), in a registered public offering pursuant to the Company’s Registration Statement on Form S-3 ASR (File No. 333-260905) (the “Registration Statement”) filed under the Securities Act of 1933, as amended, which Registration Statement became automatically effective upon filing on November 9, 2021. The Shares were sold pursuant to an Underwriting Agreement, dated October 30, 2024 (the “Underwriting Agreement”), among the Company, the Selling Shareholders and J.P. Morgan Securities LLC (the “Underwriter”). Pursuant to the terms of the Underwriting Agreement, the Selling Shareholders also granted the Underwriter a 30-day option to purchase up to 1,200,000 additional shares of Common Stock on the same terms (the “Option Shares”). The Selling Shareholders will receive all of the net proceeds from this offering. The Company will not receive any of the proceeds from this offering.
The foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety by the full text of the Underwriting Agreement, a copy of which is filed herewith as Exhibit 1.1 and is incorporated by reference herein. A copy of the opinion of Latham & Watkins LLP relating to the validity of the Shares and the Option Shares is filed herewith as Exhibit 5.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | |
| 1.1 | Underwriting Agreement, dated October 30, 2024, by and among Harmony Biosciences Holdings, Inc., J.P. Morgan Securities LLC, and certain selling shareholders named therein. | |
| 5.1 | Opinion of Latham & Watkins LLP | |
| 23.1 | Consent of Latham & Watkins LLP (included in Exhibit 5.1) | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
HARMONY BIOSCIENCES HOLDINGS, INC. | ||
| Date: November 1, 2024 | By: | /s/ Sandip Kapadia |
| Sandip Kapadia | ||
| Chief Financial Officer and Chief Administrative Officer | ||